DALLAS, Oct. 20, 2009 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring BioElectronics Corp. (Pink Sheets:BIEL). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The investment report on BioElectronics Corp. (Pink Sheets:BIEL) should be of particular interest to other medical equipment and supplies makers: Bristol Myers Squibb Co. (NYSE:BMY), 3M Company (NYSE:MMM), Diapulse Corp. (Pink Sheets:DIAC) and ADM Tronics Unlimited (OTCBB:ADMT).
It is available at: http://www.investorsoup.com/lp/BIEL
Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup
BioElectronics Corp. (BIEL) designs, develops and markets a variety of drug-free, anti-inflammatory patches for a range of medical indications. The Company's patch products, which are marketed under the name ActiPatch Therapy, deliver pulsed electromagnetic field therapy, an anti-inflammatory and pain relief therapy.
Message Board Search for BIEL: http://www.boardcentral.com/boards/BIEL
In the report, the analyst notes:
"BIEL management indicates that the financial position of the Company has improved dramatically over the past few months. Further payments have been made on convertible debentures with balances dropping from more than $910,000 one year ago to less than $50,000 today. Elimination of all convertible debenture balances is likely over the coming weeks. BIEL is maintaining very strong gross margins and tight expense controls, resulting in the Company operating at near breakeven levels. The working capital position at the Company has also significantly improved.
"BIEL recently announced it has been selected as a runner up in the medical device category of the 2009 Wall Street Journal Innovation Awards announced in Monday's global editions and online. The award was given for the Company's wearable patch that uses pulsed electromagnetic energy to deliver drug-free pain relief for a variety of conditions. David G. Genecov, M.D. FACS FAAP, provided preliminary data on a heel and foot pain study showing strong efficacy and 100% safety using the ActiPatch device. According to the Company, the study also showed that study participants were able to significantly reduce their use of acetaminophen, the active ingredient in Tylenol, and non-steroidal anti-inflammatory drugs."
To read the entire report visit: http://www.investorsoup.com/lp/BIEL
See what investors say about these stocks at: http://www.stockhideout.com/
InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup.com, please visit http://www.InvestorSoup.com .
InvestorSoup.com Disclosure
InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.